US4053651A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Compounds and method for alleviating angiotensin related hypertension
Assignee: ER Squibb and Sons LLC
•
Filing: 1976-05-10
•
Granted: 1977-10-11
•
Expires: 1996-05-10
Abstract
Abstract A method for alleviating or reducing angiotensin related hypertension in hypertensive mammals comprises administering to such hypertensive mammals an effective amount of an angiotensin converting enzyme inhibitor selected from a group of mercaptoacyl aminoacids.
Inventors
- 👤 Miguel Angel Ondetti
- 👤 David W. Cushman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 04:16
CPC Classifications
C; C07; C07C; C07C319/00; C07C319/14; C07D; C07D233/00; C07D233/54; C07D233/64; A; A61; A61P; A61P43/00; A61P9/00; A61P9/12; C07D209/00; C07D209/02; C07D209/04; C07D209/10; C07D209/18; C07D209/20
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
76 words
A method for alleviating angiotensin related hypertension in hypertensive mammals which comprises administering an effective dose of an angiotensin converting enzyme inhibitor having the formula ##STR8## or salt thereof, wherein R 1 is hydrogen, lower alkyl, phenyllower alkylene, hydroxy-lower alkylene, hydroxyphenyl-lower alkylene or guanidinolower alkylene; R 2 , R 3 and R 4 each is hydrogen, lower alkyl or phenyl-lower alkylene; R 5 is hydrogen, lower alkanoyl, benzoyl or ##STR9## n is 0, 1 or 2.
Claim 2
Independent Claim
76 words
A method for alleviating angiotensin related hypertension in hypertensive mammals which comprises administering an effective dose of an angiotensin converting enzyme inhibitor having the formula ##STR8## or salt thereof, wherein R 1 is hydrogen, lower alkyl, phenyllower alkylene, hydroxy-lower alkylene, hydroxyphenyl-lower alkylene or guanidinolower alkylene; R 2 , R 3 and R 4 each is hydrogen, lower alkyl or phenyl-lower alkylene; R 5 is hydrogen, lower alkanoyl, benzoyl or ##STR9## n is 0, 1 or 2.
Claim 3
Dependent Claim
21 words
A method as in claim 1 wherein the compound has the L-configuration with respect to the carbon bearing R 1 .
Claim 4
Dependent Claim
29 words
A method as in claim 1 wherein in the formula the group ##STR10## is derived from an amino acid of the group consisting of arginine, alanine, phenylalanine and leucine.
Claim 5
Dependent Claim
12 words
A method as in claim 1 wherein R 1 is quanidinolower alkylene.
Claim 6
Dependent Claim
12 words
A method as in claim 1 wherein R 1 is phenyllower alkylene.
Claim 7
Dependent Claim
12 words
A method as in claim 1 wherein R 1 is lower alkyl.
Claim 8
Dependent Claim
19 words
A method as in claim 2 wherein the dosage is about 10 to 500 mg. per kilogram per day.
Claim 9
Dependent Claim
35 words
A method as in claim 2 wherein the compound in the formula has R 1 as guanidinopropyl, R 2 , R 3 , R 4 and R 5 each as hydrogen and n as 1.
Claim 10
Dependent Claim
36 words
A method as in claim 2 wherein the compound in the formula has R 1 as guanidinopropyl, R 2 , R 4 and R 5 each as hydrogen, R 3 as methyl and n as 1.
Claim 11
Dependent Claim
35 words
A method as in claim 2 wherein the compound in the formula has R 1 as phenylmethyl, R 2 , R 3 , R 4 and R 5 each as hydrogen and n as 1.
Claim 12
Dependent Claim
35 words
A method as in claim 2 wherein the compound in the formula has R 1 as isobutyl, R 2 , R 3 , R 4 and R 5 each as hydrogen and n as 1.
References Cited (Backward Citations)
US3246025A
Cited
US3857951A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-10-10 | 1981-04-11 | 1981-10-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-10-10 | 1985-04-11 | 1985-10-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-10-10 | 1989-04-11 | 1989-10-11 | $7700.00 | Window Closed / Lapsed |